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Background: Mammalian target of rapamycin (mTOR) inhibitors are associated with dermatological adverse events.
The chief aim of this study was to examine the relation between the signal transducer and activator of transcription
3 (STAT3) protein and the dermatological adverse events associated with the mTOR inhibitor everolimus.
Methods: We evaluated the effects of STAT3 activity and related signal transduction activities on everolimus-
induced cell growth inhibition in the human keratinocyte HaCaT cell line via a WST-8 assay, and on signal
transduction mechanisms involved in everolimus treatments via a western blot analysis. Apoptosis was evaluated
using an imaging cytometric assay.
Results: The cell growth inhibitory effects of everolimus were enhanced by stattic or STA-21, which are selective
inhibitors of STAT3, treatment in HaCaT cells, although such effects were not observed in Caki-1 and HepG2 cells.
Phosphorylation at tyrosine 705 of STAT3 was decreased by treatment with everolimus in a dose-dependent
manner in HaCaT cells; in contrast, phosphorylation at serine 727 was not decreased by everolimus, but slightly
increased. Furthermore, we found that pretreatment of p38 MAPK inhibitor and transfection with constitutively
active form of STAT3 in HaCaT cells resisted the cytostatic activity of everolimus.
Conclusions: These findings suggest that STAT3 activity may be a biomarker of everolimus-induced dermatological
toxicity.
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Cancer chemotherapy made dramatic progress with the
advent of molecular target drugs. Development of these
molecules for the treatment of various types of cancer is
expected in the future. However, serious adverse events
were observed with continuous treatment of cancer by
molecular target drugs that are considered as more safe
therapeutic options. In particular, dermatological adverse
events, sometimes termed as “hand–foot skin reaction”,
occur at an exceptionally high frequency during the use of
specific drugs thus leading to interruption of therapy or
depression in quality of life [1-4]. These dermatological
side effects are differentiated from dermatitis resulting
from cytotoxic anticancer agents, e.g., 5-fluorouracil and* Correspondence: yamakz@med.kobe-u.ac.jp
1Department of Pharmacy, Kobe University Hospital, 7-5-2 Kusunoki-cho,
Chuo-ku, Kobe 650-0017, Japan
Full list of author information is available at the end of the article
© 2013 Yamamoto et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumdrugs in the taxane group, and they exhibit a characteristic
pathological model [3]. Furthermore, clinicopathological
findings have shown that these dermatological side effects
are due to deficiency in epidermal cell growth [5]. In
addition, these effects are present in a localized area of the
body [5]. Moreover, these side effects are correlated with
therapeutic effects [3-5]. Although they pose a critical
issue for patients receiving targeted molecular therapy, the
pathogenic mechanisms underlying these side effects re-
main unclear.
Mammalian target of rapamycin (mTOR) inhibitors
(rapamycin, everolimus, and temsirolimus) are a new
class of anticancer drugs with a novel mechanism of ac-
tion. These compounds inhibit the proliferation and
growth of a wide spectrum of tumor cell lines by inhibit-
ing signal transduction from the phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (Akt)/mTOR pathway
[6]. The potential benefits of mTOR inhibitors have nottral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Chemical structure of everolimus.
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these drugs. The incidence of dermatitis in sirolimus-
treated patients is in the range of 13–46% in different
studies [7-9]. An effective breakthrough regarding the
cutaneous side effects of treatment with mTOR inhibi-
tors remains crucial.
The signal transducer and activator of transcription
(STAT) signaling pathways are activated in response to cy-
tokines and growth factors [e.g., epidermal growth factor
(EGF) and vascular endothelial growth factor (VEGF)]
[10,11]. STAT3 exerts widespread effects via the transcrip-
tional upregulation of genes encoding proteins involved in
cell survival, cell–cycle progression, and homeostasis
[12,13]. Moreover, transcription mediated by phosphory-
lated STAT3 (pSTAT3) controls several genes of the apop-
totic pathway, including the bcl family and inhibitors of
apoptosis family of genes [14]. A recent study reported
that STAT3 is the main factor in the molecular control of
cutaneous homeostasis [15]. Inhibition of STAT3 (as an
important factor in the formation of skin lesions) has the
potential to be one of the pathogenic mechanisms under-
lying the dermatological side effects induced by treatment
with molecular target drugs.
In the present study, we investigated the effects of
STAT3 and related mechanisms on everolimus-mediated
cell growth inhibition in human epidermal keratinocyte
cell lines. Our findings suggest that STAT3 activity in




Everolimus (Figure 1), a derivative of sirolimus and an
mTOR inhibitor, was purchased from Sigma-Aldrich
Chemical, Co. (St Louis, MO, USA). Stattic, a small-
molecule inhibitor of STAT3 activation [16], was purchased
from Enzo Life Sciences, Inc. (Farmingdale, NY, USA).
STA-21, a STAT3 inhibitor [17], was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Z3, an
inhibitor of the autophosphorylation of Janus kinase 2
(JAK2) [18], was obtained from Calbiochem (Darmstadt,
Germany). SB203580, a specific blocker of p38 mitogen-
activated protein kinase (MAPK) activity, and SP600125,
a selective and reversible inhibitor of the c-Jun N-terminal
kinase 1 (JNK1), JNK2, and JNK3, were obtained from
Cayman Chemical Company (Ann Arbor, MI, USA).
U0126, a selective inhibitor of mitogen-induced extracel-
lular kinase 1 (MEK1) and MEK2, was purchase from Cell
Signaling Technology, Inc. (Boston, MA, USA).
Antibodies
Rabbit anti-phosphorylated (anti-phospho)-STAT3 at
tyrosine 705 (Tyr705) and serine 727 (Ser727), mouse anti-
STAT3 antibodies, rabbit anti-phospho-extracellular signal-regulated kinase (Erk) 1/2, rabbit anti-Erk 1/2 antibodies,
rabbit anti-phospho-p38 MAPK, rabbit anti-p38 antibodies,
anti-phospho-S6 kinase (Thr389) and anti-p70 S6 kinase
antibodies were purchased from Cell Signaling Technology.
Mouse anti-phospho-JNK and rabbit anti-JNK antibodies,
as well as anti-mouse HRP-conjugated IgG, anti-rabbit
HRP-conjugated IgG, and anti-rabbit FITC-conjugate IgG,
were purchased from Santa Cruz Biotechnology. A rabbit
anti-β-actin antibody was obtained from Sigma-Aldrich.
Cells and cell culture
HaCaT cells, the human immortalized keratinocyte cell
lines, were kindly provided by Professor Norbert Fusenig
(German Cancer Research Centre, Heidelberg, Germany)
[19]. HepG2 cells, the human hepatocarcinoma cell lines,
were purchased from JCRB (Osaka, Japan). HaCaT and
HepG2 cells were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma-Aldrich) supplemented
with 10% heat-inactivated fetal bovine serum (lot. No.
9866 J; MP Biomedicals, Solon, OH, USA), 100 units/
mL of penicillin, and 100 μg/mL streptomycin (Life
Technologies, Carlsbad, CA, USA). Caki-1 cells, the
human renal cell carcinoma cell lines, were purchased
from JCRB. Caki-1 cells were maintained in Eagle’s
Minimum Essential Medium (EMEM; Sigma-Aldrich)
supplemented with 10% heat-inactivated fetal bovine
serum, 100 units/mL of penicillin, and 100 μg/mL
streptomycin, similar to the HaCaT culture medium.
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humidified atmosphere of 5% CO2 and 95% air at 37°C,
and subcultured with 0.05% trypsin/0.02% EDTA (Life
Technologies).
WST-8 colorimetric assay
The effects of various signal transduction inhibitors and
transfection with expression plasmids on the everolimus-
mediated cell growth inhibition in HaCaTcells were evalu-
ated via the WST-8 assay using the Cell Counting Kit-8
(Dojindo Laboratories, Kumamoto, Japan) as described
previously [20-22]. Cells (2 × 103/well) were seeded onto
96-well plates and precultured for 24 h. The medium was
exchanged for medium containing everolimus at various
concentrations after pretreatment with signal transduction
inhibitors at several concentrations, for appropriate term,
followed by incubation for 48 h at 37°C. The culture
medium was replaced with a medium containing a WST-8
reagent for 3 h and the absorbance in the well was deter-
mined at 450 nm with a reference wavelength of 630 nm
using a microplate reader (FLUOstar OPTIMA, BMG
LABTECH, Ltd., Germany).
Apoptosis assay
Apoptosis-mediated cell death was examined in HaCaT
cells by a double-staining method using a FITC-labeled
Annexin V/propidium iodide (PI) apoptosis detection kit
(BD Biosciences, San Jose, CA, USA) according to the man-
ufacturer’s instructions. In brief, control, everolimus-treated,
and stattic-treated cells were washed in phosphate-buffered
saline (PBS) twice and incubated with PBS containing FITC-
conjugated Annexin V and PI dyes for 30 min at 37°C.
After cells were washed in PBS twice, they were incubated
with PBS containing 10 μM Hoechst 33258 and 4% para-
formaldehyde for 30 min at 37°C. The externalization
of phosphatidylserine and the permeability to PI were
evaluated using an IN Cell Analyzer 2000 (GE Healthcare
UK Ltd, Buckinghamshire, UK). Cells in early stages of
apoptosis were positively stained with Annexin V, whereas
cells in late apoptosis were positively stained with both
Annexin V and PI.
Western blotting
Western blotting was performed as described previously
[6]. Proteins in the total cell lysate were extracted from
cells treating to each buffer with Cell Lysis Buffer (Cell
Signaling Technology) in addition to 1 mM dithiothrei-
tol, 1 mM phenylmethylsulfonyl fluoride, and 5 μg/mL
leupeptin. Proteins were separated using 7.5 or 12%
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE)
electrophoresis and electrotransferred to a polyvinylidene
difluoride membrane (Hybond-P membrane; GE Health-
care). Subsequently, the blot was blocked in a solution
of wash buffer (10 mM Tris, pH 7.5, 150 mM NaCl,and 0.05% Tween-20) containing 5% skim milk. The
membrane was soused in wash buffer containing specific
primary antibodies overnight, followed by incubation with
horseradish peroxidase-conjugated secondary antibodies
for 1 h. Antibody-bound proteins were visualized by treat-
ing the membrane with the enhanced ECLTM Prime
Western Blotting Detection Reagent (GE Healthcare) pre-
pared immediately before detection. Finally, blot im-
ages were acquired using ChemiStage 16-CC (KURABO
Industries Ltd., Osaka, Japan). Wherever indicated,
the membranes were stripped and reprobed with another
antibody.
Plasmid construction
Constitutively active STAT3 (STAT3C) mammalian ex-
pression plasmids were kindly provided by Professor
Miyajima (University of Tokyo, Tokyo, Japan) [23]. Tyro-
sine 705 deficient STAT3 (STAT3-Y705F) mammalian
expression plasmids were kindly provided by Darnell
(Addgene plasmid #8709) [24]. STAT3C and STAT3-Y705F
constructs were transformed into DH-5α competent cells
and plasmid DNA was extracted using the QIAGEN® Plas-
mid Midi Kit (QIAGEN K.K, Tokyo, Japan). Extracted plas-
mids were purified to a grade appropriate for cell culture
using phenol and chloroform and stocked at 1 μg/μL in a
freezer until experimental use.
Transient transfection
Transient transfection of cell lines with expression vec-
tors was performed using the Lipofectamine LTX trans-
fection reagent (Life Technologies) according to the
manufacturer’s protocol. In brief, cells were grown in
96-well culture plates until they reached ~90% conflu-
ence. The culture medium was replaced with serum-free
Opti-MEM (Life Technologies) and cells were trans-
fected with the DNA–lipofectamine complex. HaCaT
cells were transiently transfected with 0.1 μg/well of
plasmid in 96-well plates.
Immunofluorescence imaging and cytometric analysis
Transfected HaCaT cells were fixed with 4% paraformal-
dehyde for 15 min at room temperature and blocked
in 5% BSA. And the cells were incubated with an
anti-STAT3 antibody, followed by incubation with FITC-
conjugated anti-rabbit IgG (Santa Cruz) and PI for stain-
ing nuclei. Visualized on an IN Cell Analyzer 2000, image
acquisition was configured to yield at least 1,000 cells
per replicate well. Cytometric analysis performed with
IN Cell Analyzer Workstation version 3.2. STAT3 nu-
clear entry was determined by measuring the nucleus/
cytoplasm intensity ratio of green fluorescence with
the Nuclear Translocation analysis module. Represen-
tatives of STAT3 nuclear translocation were shown as
means ± SD.
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Statistical analysis was performed using a nonrepeated
one-way analysis of variance followed by the Dunnett test
for multiple comparisons. p values < 0.01 (two-tailed) were
considered significant.
Results
Effects of stattic on everolimus-induced cell growth
inhibition in various cell lines
Figure 2 shows the everolimus-induced cell growth in-
hibition in HaCaT, Caki-1, and HepG2 cells in the ab-
sence or presence of the STAT3 inhibitor stattic. We
found that the everolimus-induced cell growth inhibition
in HaCaT cells was enhanced by pretreatment with stat-
tic. In contrast, the everolimus-induced cell growth in-
hibition in Caki-1 and HepG2 cells was unaffected by
stattic treatment. There was no significant difference on
absorbance values with cell toxicity of control and stattic
as not including everolimus in these cells.
Effects of STAT3 inhibitors on apoptotic effects in HaCaT
cells
To confirm that the apoptotic effects of everolimus were
enhanced by pretreatment with stattic, we performed an
apoptosis assay (Figure 3A). Imaging cytometric analysis
of apoptotic cells by Annexin V/PI staining showed that
apoptosis in HaCaT cells was increased after everolimus
treatment in a dose-dependent manner. Moreover, the
percentage of apoptotic cells was enhanced by stattic
pretreatment. These results indicate that stattic pretreat-
ment enhances the apoptotic effects of everolimus in
HaCaT cells.
Effects of various JAK/STAT pathway inhibitors on
everolimus-induced cell growth inhibition in HaCaT cells
In the presence of another STAT3 inhibitor (STA-21),










































Figure 2 Effects of a STAT3 inhibitor on the everolimus-induced cell g
and HepG2 cells were incubated in medium containing everolimus at the
or DMSO (a solvent of stattic) for 20 min. Cell viability was determined by W
control (DMSO). There was no significant difference in cell toxicity in the Din HaCaT cells was also enhanced, whereas a JAK2 in-
hibitor (Z3) did not affect the everolimus-induced cell
growth inhibition (Figure 3). This synergistic cell growth
inhibition effect was not due to coincubation with IL-6.
Effects of everolimus and STAT3 inhibitors on signal
transduction in HaCaT cells
Signal transduction in the presence of everolimus and
pretreatment with stattic in HaCaT cells is shown in
Figure 4. Phosphorylation of Tyr705 of STAT3 was
decreased after treatment with everolimus for 2 h in
a dose-dependent manner in HaCaT cells. In contrast,
phosphorylation of Ser727 of STAT3 was unaffected by
everolimus treatment in HaCaT cells in the absence of
stattic; however, it increased slightly in the presence of
stattic. Tyr705 phosphorylation was decreased by treat-
ment with everolimus in the presence of pretreatment
with stattic. Moreover, to clarify how STAT3 and mTOR
regulate cell toxicity whether in a parallel manner or in a
downstream regulation, we examined if STAT3 activity
varies in a time-dependent manner with treatment of
everolimus (Figure 4B). Phosphorylation of STAT3 was
decreased in short-term but increased in long-term incu-
bated with low-dose everolimus. Phosphorylation of p70
S6K which is direct downstream of mTORC1 showed
inhibition in a time-dependent manner based on the
mechanism of action of everolimus. This results show that
STAT3 phosphorylation can be regulated indirectly by
mTOR.
Effects of everolimus on MAPKs activity in HaCaT cells
and effects of MAPK inhibitors on everolimus-induced cell
growth inhibition in HaCaT cells
Previous studies demonstrated that the PI3K/Akt/mTOR
and MAPK pathways represent a cross-linked signal net-
work in various cell lines, and that STAT3 is an import-
ant downstream signaling factor of these pathwaysHepG2 cells














rowth inhibition in HaCaT, Caki-1, and HepG2 cells. HaCaT, Caki-1,
indicated concentrations for 48 h after pretreatment with 10 μM stattic
ST-8 colorimetric assay. *p < 0.01 Student’s t test compared with
MSO, stattic, and 0 μM everolimus conditions for each cell line.
A B
Figure 3 Effects of various STAT3 pathway inhibitors on everolimus-mediated apoptotic effects and cell growth inhibition in HaCaT
cells. (A) HaCaT cells were incubated in medium containing everolimus at the indicated concentrations for 48 h after pretreatment with 10 μM
stattic or DMSO for 20 min. Subsequently, apoptotic cells were detected using FITC-labeled Annexin V/PI staining on an IN Cell Analyzer 2000 for
Imaging cytometric analysis. (B) Effects of JAK/STAT pathway inhibitors and IL-6 on the cell growth inhibition induced by everolimus. HaCaT cells
were incubated in medium containing 30 μM everolimus for 48 h after pretreatment with 10 μM stattic for 20 min or coincubation with everolimus
and 25 μM Z3 (a selective inhibitor of JAK2), 20 μM STA-21, 100 ng/mL IL-6, or DMSO (solvent of these inhibitors). Cell viability was determined by
WST-8 colorimetric assay.
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phosphorylation of JNK, Erk1/2, and p38 MAPK after
treatment with everolimus in HaCaT cells (Figure 5A).
The phosphorylation of Erk1/2 and p38 MAPK was
increased after treatment with everolimus in a dose-
dependent manner in HaCaT cells. Moreover, the phos-
phorylation of p38 MAPK was particularly increased in
the presence of pretreatment with stattic. Figure 5B
shows the everolimus-induced cell growth inhibition
in HaCaT cells in the absence or presence of a MEK1/2
inhibitor (U0126), a p38 MAPK inhibitor (SB203580) or
a JNK inhibitor (SP600125). Treatment with the p38
MAPK inhibitor reduced the efficacy of cell growth
inhibition by everolimus in HaCaT cells. A MEK1/20 10 20 50
HaCaT cells
(1) DMSO (2) stattic (10 µM) (3) STA-21Inhibitor
Everolimus (µM)
0 10 20 50 0 10
A
Figure 4 Effects of various STAT3 inhibitors on everolimus-mediated
of STAT3. HaCaT cells were incubated in medium containing everolimus at th
stattic for 20 min or (2): coincubation with everolimus and 10 μM STA-21 or (3
HaCaT cells were incubated in medium containing 10 μM everolimus at the i
electrotransferred to PVDF membranes. Various proteins and phosphorylationinhibitor also affect the everolimus-induced cell
growth inhibition in HaCaT cells, slightly. Moreover,
we examined a possibility that MAPKs inhibitors rescue
the inhibition of phosphorylation of STAT3 by everolimus
(Figure 5C). In the pretreatment of SB203580, STAT3
Tyr705 phosphorylation was enhanced comparing from
treatment of everolimus alone.
Effects of STAT3 Y705F and STAT3C transfection on
everolimus-induced cell growth inhibition in HaCaT cells
STAT3C is a constitutively active STAT3 that dimerizes
constantly by substituting cysteine residues for specific
amino acids within the C-terminal loop of the STAT3
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Figure 5 Effects of everolimus on MAPKs activation in HaCaT and effects of MAPK inhibitors on everolimus-induced cell growth
inhibition and signal transduction. (A) Alterations in the signal transduction of MAPKs. HaCaT cells were incubated in medium containing
everolimus at the indicated concentrations for 2 h after pretreatment with 10 μM stattic or DMSO. Total cell lysates were separated by SDS-PAGE
and electrotransferred to PVDF membranes. Various proteins and phosphorylation levels were evaluated by immunoblotting assay with specific
antibodies. (B) Effects of MAPK inhibitors on everolimus-induced cell growth inhibition. HaCaT cells were incubated with medium containing
everolimus at the indicated concentrations for 48 h after pretreatment with U0126 (a MEK1/2 inhibitor, 10 μM) for 2 h, SB203580 (a p38 MAPK
inhibitor, 10 μM) for 1 h, SP600125 (a JNK inhibitor, 20 μM) for 30 min, or DMSO (their solvent) for 2 h. Cell viability was determined by WST-8
colorimetric assay. *p < 0.01 Student’s t test compared with control (DMSO). Each bar represents the mean ± SD (n = 4). (C) Alterations in the
signal transduction of STAT3 in the presence of MAPKs inhibitor. HaCaT cells were incubated in medium containing 30 μM everolimus for 2 h
after pretreatment with 10 μM stattic for 20 min (st), 10 μM U0126 for 2 h (U), 10 μM SB203580 for 1 h (SB), 20 μM SP600125 for 30 min (SP) or
DMSO (D). Total cell lysates were separated by SDS-PAGE and electrotransferred to PVDF membranes. Various proteins and phosphorylation levels
were evaluated by immunoblotting assay with specific antibodies.
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Transfection of cells with STAT3 Y705F had a tendency
to enhance the cellular toxicity of everolimus compared
with transfection with an empty vector, but STAT3C had
a tendency to relieve, as shown in Figure 6A.
Discussion
A recent study reported that common cutaneous derma-
tological side effects develop after treatment with EGF
receptor (EGFR) inhibitors (e.g., cetuximab, panitumu-
mab, and erlotinib), mTOR inhibitors (e.g., everolimus
and temsirolimus), and multikinase inhibitors (e.g., so-
rafenib and sunitinib) [1-5,7-9,28-30]. These drugs exert
a beneficial effect by inhibiting a close line of signaltransduction; therefore, we thought that the key factor
involved in the dermatological events observed may be a
downstream factor converging from PI3K and MAPK
pathways. STAT3 is activated by stimulation from PI3K,
MAPK, and JAK2 pathways; thus, we hypothesized that
STAT3 is a candidate factor for regulating dermato-
logical events induced by molecular target drugs.
Cell growth inhibition by everolimus in HaCaT cells
was enhanced by pretreatment with STAT3 inhibitors
(stattic and STA-21), but not by pretreatment with a
JAK2 inhibitor (Figures 2 and 3B). We interpreted this
phenomenon in the following manner: the everolimus-
induced cell growth inhibition involved in STAT3 in ker-










































































Figure 6 Effects of dominant negative and constitutively active STAT3 on everolimus-induced cell growth inhibition in HaCaT cells.
(A) Effects of STAT3 Y705F and STAT3C transfection on everolimus-induced cell growth inhibition. HaCaT cells transiently transfected with STAT3
Y705F, STAT3C or each empty vector were incubated in medium containing everolimus at the indicated concentrations for 48 h after preincubation
for 24 h. Cell viability was determined by WST-8 colorimetric assay. *p < 0.01 Student’s t test compared with control (DMSO). There was no significant
difference in the cell toxicity between the empty vector and STAT3C transfection. (B) Immunostaining images. HaCaT cells transiently transfected with
STAT3C or empty vector were fixed and incubated with an anti-Stat3 antibody, followed by incubation with FITC-conjugated anti-rabbit IgG (green)
and visualization on an IN Cell Analyzer 2000. (C) STAT3 nuclear entry was determined by measuring the nucleus/cytoplasm intensity ratio of green
fluorescence (n = 3). *p < 0.05 Student’s t test compared with control.
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JAK2 pathway. Everolimus and STAT3 inhibitors inhibited
cell growth synergistically and increased the number of
apoptotic cells (Figure 3A), but there was a little difference
between the survival data and the apoptosis data. A cause
of this difference considered that treatment time between
cell survival analysis and apoptosis analysis was differed.
In the cell survival analysis, each cell was treated with
everolimus for 48 h, but in the apoptosis analysis, HaCaT
cells were incubated with everolimus for 24 h, because it
was necessary that cell spacing be got at the point of
measurement to evaluate apoptosis marker appropriately
in imaging cytometric analysis. Incubating for 48 h in con-
trol cells could not get adequate cell spacing. Moreover,
STAT3 activation is suggested to differ between human
immortalized keratinocyte HaCaT cells and normal hu-
man keratinocytes [31]. We confirmed that everolimus-
induced cell growth inhibition was enhanced by STAT3
inhibition in normal human epidermal keratinocyte
NHEK cells (data not shown). Because similar results were
obtained in our study using NHEK cells, we suggest that
the same phenomenon may occur in normal keratinocyte
cells characterized of having less STAT3 activity. Inaddition, our study showed that cell survival differed in
each cell type in the presence of STAT3 inhibitors. This
suggests that stattic behaved similarly in each cell line, but
may differ greatly depending on cell types that contribut-
ing rate of STAT3 in the cell survival.
Another recent study reported that cooperation of the
two phosphorylated residues is necessary for the full ac-
tivation of STAT3 [31-34]. In our study, Tyr705 phos-
phorylation was decreased by treatment with everolimus
in a dose dependent manner in short-term treatment,
however in long-term for 12–24 h, Tyr705 phosphoryl-
ation increase by treatment with low-concentration
everolimus in HaCaT cells. Ser727 phosphorylation was not
decreased, rather, it was slightly increased in short-term
treatment, but in long-term for 12–24 h, Ser727 phosphor-
ylation decrease by treatment with low-concentration
everolimus (Figure 4). Stattic inhibits Tyr705 phosphoryl-
ation and the dimerization of STAT3 molecules, and
Ser727 phosphorylation should not be affected by stattic
[16]. This results show that Tyr705 phosphorylation can be
regulated indirectly by mTOR. It is known that a mTOR in-
hibitor cause compensatory activation of MAPKs signal
[35,36]. And, It is also known that MAPKs regulate STAT3
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phosphorylation of STAT3 by everolimus mediate MAPKs
pathway.
It is well known that the STAT3 Ser727 residue is
phosphorylated mainly by Erk1/2, p38 MAPK, JNK and
mTOR [37-40]. Our results showed that everolimus acti-
vated Erk and p38 MAPK and phosphorylated STAT3 at
Ser727, which SB203580 inhibited phosphorylation of
STAT3 at Ser727 (Figures 4 and 5). A negative effect of
Ser727 phosphorylation on Tyr705 phosphorylation in
STAT3 has also been suggested [41]. These results sup-
port those of previous reports showing that activated
Erk and p38 may synergistically regulate STAT3 activity
in a negative manner. In addition, although JNK did not
affect everolimus-mediated cell growth inhibition, the
p38 MAPK inhibitor depressed everolimus-induced cell
growth inhibition in HaCaT cells (Figure 5). The phos-
phorylation of p38 MAPK was increased by exposure to
everolimus, and inhibition of phosphorylation of STAT3
Tyr705 by everolimus rescued by pretreatment of
SB203580. mTOR inhibition by everolimus results in in-
hibition of de novo protein synthesis, and results in p38
MAPK activation due to sense cellular stress, moreover
they may result in STAT3 inhibition [35]. We considered
that p38 MAPK may be largely involved in the everolimus-
induced inhibition of STAT3 activity in keratinocytes. So,
Erk phosphorylation was also activated by everolimus and
U0126 depressed everolimus-induced cell growth inhib-
ition slightly in HaCaT cells. It is well known that Erk
regulate STAT3 activity negatively [38]. Erk activity
may partially contribute to everolimus-induced cell growth
inhibition in keratinocyte. p38 MAPK pathways are known
as stress response signals and interact with the PI3K/Akt/
mTOR pathway [36]. Recently, it was reported that kera-
tinocyte apoptosis induced by gefitinib, which is a selective
EGFR tyrosine kinase inhibitor, is mediated by the JNK
activation pathway [42]. This study did not reproduce the
results of that report; therefore, the mechanisms under-
lying everolimus-induced keratinocyte apoptosis may differ
from those underlying gefitinib-induced apoptosis. Alter-
natively, they may be one of the gefitinib-induced mecha-
nisms because the gefitinib target signal lies upstream
from the target of everolimus.
In addition, because STAT3 Y705F enhanced cell toxicity
in HaCaT cells and STAT3C relived, the survival of this
type of keratinocytes may depend largely on STAT3
(Figure 6). For comparison, we considered that an active
form of STAT3 subtly rescued everolimus-induced toxicity
because cell temporary transfection efficiency of pcDNA3
STAT3C with lipofection method in HaCaT cells was not
higher as a result of confirming STAT3 expressions with
western blotting assay. To corroborate this effects of rescue
by STAT3C, it’s necessary in the future to conduct an
experiments with HaCaT cells stably expressed STAT3C.Previous reports have suggested that STAT3 inhibition
in cutaneous squamous cell carcinoma induces senescence
and not apoptosis [43]. Though apoptosis suppressing
genes (e.g., bcl-2) and senescence factors (e.g., AP-1) were
not evaluated in our study, both apoptotic and senescent
effects may have affected the cell growth inhibition in-
duced by everolimus and the STAT3 inhibitor. In addition,
the apoptotic effects observed in our study may have been
enhanced by interaction with the effects of mTOR and
STAT3 inhibition.
Everolimus is distributed by P-glycoproteins and me-
tabolized by CYP3A4 [44,45]. Although the pharmacoki-
netic profiles of stattic have not been clarified, there is
no denying that the interactions between everolimus and
stattic are due to pharmacokinetic actions. We have pre-
viously demonstrated that calcium antagonists and α-
adrenoceptor antagonists enhanced cellular sensitivity to
SN-38, an active metabolite of irinotecan, by increasing
the concentration of SN-38 in cells [21,22]. It is difficult
to assume that a similar phenomenon caused the effects
observed in this study; however, the involvement of
STAT3 may be the greater part of this interaction be-
cause a similar phenomenon was caused by STA-21,
which has a chemical structure that is different from
that of stattic, and STAT3C transfection moderated
everolimus-induced cell growth inhibition.
In clinical practice, it is known that the efficacy of mo-
lecular target drugs is correlated with their toxicity. It
has been reported that inhibition of STAT3 by sunitinib
contributes to the induction of apoptosis in renal cell
carcinoma [46]. Moreover, STAT3 is known to have
functional single nucleotide polymorphisms (SNPs).
These SNPs have been reported to be predictive tools
for the efficacy of IFN treatment against metastatic renal
cell carcinoma [47]. Based on these reports and the
present study, we hypothesized that STAT3 would be a
critical factor for the treatment of renal cell carcinoma
and toxicity to skin tissue, and that responsibility of
STAT3 depend on functional SNPs. However, it remains
unclear that the everolimus-induced cell growth inhib-
ition in Caki-1 and HepG2 cells was unaffected by stattic
treatment. SNPs genotyping analysis of STAT3 in vari-
ous cells is required to address these issues in the future.
In addition, through our research, patients carrying a
high risk of dermatological toxicity by molecular target
drugs could be identified by testing for STAT3 polymor-
phisms. And, ultraviolet (UV) irradiation increases the
potential of dermatological side effects induced by mo-
lecular target drugs in clinical reports [48]. STAT3 rep-
resents a critical regulator of keratinocytes in response
to UVB irradiation [49]. After UVB irradiation, STAT3 is
rapidly downregulated in keratinocytes, which leads to
decreased cell cycle progression and increased sensitivity
to UVB-induced apoptosis. It has also been reported that
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STAT3 [50]. Furthermore, UV triggers the activation of
members of the MAPK family, including Erk1/2, JNK, and
p38 MAPK [50]. UV irradiation can enhance MAPK activ-
ity and lead to a greater phosphorylation of STAT3 at
Ser727 in the presence of everolimus [26,51]. These re-
sults suggest that the dermatological side effects induced
by molecular target drugs can be increased potentially by
UV irradiation, with repression of STAT3 activity mediat-
ing greater phosphorylation of Ser727. However, add-
itional studies are necessary to clarify this potency.
Conclusions
In conclusion, STAT3 activation may be a key factor
in everolimus-induced keratinocyte cytotoxicity. More-
over, p38 MAPK and Erk mediated between mTOR
signaling and STAT3 signaling may also play an im-
portant role of everolimus-induced dermatological side
effects. Skin reactions caused by everolimus or other
molecular target drugs may cause significant physical
discomfort, thus decreasing the quality of life of pa-
tients or leading to the discontinuation of drug ther-
apy. Therefore, a mechanism-based approach, and not
just clinical experience-based treatment strategies, to
assess dermatological toxicity should be proposed to
overcome this uncomfortable reaction. We advocate
that cutaneous localized treatment aimed at the main-
tenance of the homeostasis of STAT3 activity may be
an effective strategy.
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